Skip to main content
Michael Paradowski

Dr Michael Paradowski

Senior Research Fellow

School of Biosciences

Email
ParadowskiM@cardiff.ac.uk
Telephone
+44 29225 10847
Campuses
Main Building, Park Place, Cardiff, CF10 3AT

Overview

Michael has >20 year experience as a medicinal chemist in drug discovery, working for the pharmaceutical industry (Pfizer) and drug discovery groups within academia (University of Sussex, Cardiff University). Michael has extensive experience working across a range of target classes and disease areas encompassing anti-infectives, allergy & respiratory and CNS.

Michael is currently a Senior Research Scientist at Cardiff University where he was responsible for establishing the chemistry and biology laboratories at the Medicines Discovery Institute. Michael's current research interests are in CNS ion channels and in particular modulators of the GABAA receptors (Anxiety disorders, Neuropathic pain, Post-Partum depression, Psychosis, Epilepsy) where he is leading a portfolio of projects from early discovery to late stage pre-clinical studies.

Before joining the Medicines Discovery Institutes, Michael setup the research laboratories within the Sussex Drug Discovery group where he invented Sisunatovir (RV521), an inhibitor of respiratory syncytial virus

As a project leader for Pfizer, Michael led multiple global chemistry teams, both in-house and externally to enable delivery of molecules from hit-to-lead through to candidate molecule scale up to support Phase 1 studies and has been involved in the discovery of Maraviroc and numerous Phase I and II clinical candidates

Michael graduated from the French Grandes Ecoles d'ingénieurs ENSI Caen and holds a Ph.D. in Chemistry from the University of Sussex and is author and inventor on multiple patents and publications

Publication

2024

2021

2019

2017

2016

Erthyglau

Patentau

Research

Michael's current research interests are in CNS ion channels and in particular modulators of the GABAA receptors (Anxiety disorders, Neuropathic pain, Post-Partum depression, Psychosis, Epilepsy)

Project Leader for MRC funded non-sedating anxiolytic a2/3-GABA subtype selective modulator

Project leader for Wellcome Trust Innovator Award: Developing small molecules as a neurosteroid replacement strategy for treating postpartum psychosis

Biography

Michael has >20 year experience as a medicinal chemist in drug discovery, working for the pharmaceutical industry (Pfizer) and drug discovery groups within academia (University of Sussex, Cardiff University). Michael has extensive experience working across a range of target classes and disease areas encompassing anti-infectives, allergy & respiratory and CNS.

Michael is currently a Senior Research Scientist at Cardiff University where he was responsible for establishing the chemistry and biology laboratories at the Medicines Discovery Institute. Michael's current research interests are in CNS ion channels and in particular modulators of the GABAA receptors (Anxiety disorders, Neuropathic pain, Post-Partum depression, Psychosis, Epilepsy) where he is leading a portfolio of projects from early discovery to late stage pre-clinical studies.

Before joining the Medicines Discovery Institutes, Michael setup the research laboratories within the Sussex Drug Discovery group where he invented Sisunatovir (RV521), an inhibitor of respiratory syncytial virus

As a project leader for Pfizer, Michael led multiple global chemistry teams, both in-house and externally to enable delivery of molecules from hit-to-lead through to candidate molecule scale up to support Phase 1 studies and has been involved in the discovery of Maraviroc and numerous Phase I and II clinical candidates

Michael graduated from the French Grandes Ecoles d'ingénieurs ENSI Caen and holds a Ph.D. in Chemistry from the University of Sussex and is author and inventor on multiple patents and publications